Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

This study has been terminated.
(Difficulties in logistics handling the very severe patients (travel, hospital stay, follow-up))
Information provided by (Responsible Party):
Haukeland University Hospital Identifier:
First received: July 2, 2010
Last updated: April 11, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)